NVCR - Novocure creates new CNS focused franchise to renew growth in brain cancer business

• Oncology company Novocure ( NASDAQ: NVCR ) on Wednesday announced the creation of a central nervous system focused cancers franchise.
• NVCR's chief development officer Frank Leonard was named president of the new organization, U.S. CNS Cancers Franchise.
• The franchise was "intended to renew focus on growth in Novocure’s glioblastoma (GBM) business," NVCR said in a statement .
• NVCR in July reported a wider-than-expected Q2 loss on the back of increased costs.
• "This new organization will add resources, streamline decision-making and improve coordination," the company added.
• NVCR stock +2.5% to $84.50 in premarket trading.

For further details see: